ARS Pharmaceuticals, Inc. to Post Q1 2025 Earnings of ($0.19) Per Share, William Blair Forecasts (NASDAQ:SPRY)

ARS Pharmaceuticals, Inc. (NASDAQ:SPRYFree Report) – Analysts at William Blair issued their Q1 2025 earnings estimates for ARS Pharmaceuticals in a research note issued to investors on Friday, March 22nd. William Blair analyst T. Lugo forecasts that the company will earn ($0.19) per share for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for ARS Pharmaceuticals’ current full-year earnings is ($0.75) per share. William Blair also issued estimates for ARS Pharmaceuticals’ Q2 2025 earnings at ($0.14) EPS, Q3 2025 earnings at ($0.04) EPS and Q4 2025 earnings at ($0.08) EPS.

Several other brokerages also recently issued reports on SPRY. Wedbush reissued an “outperform” rating and set a $19.00 price objective on shares of ARS Pharmaceuticals in a research report on Monday, March 11th. Leerink Partnrs raised shares of ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 5th. Finally, SVB Leerink raised shares of ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating and increased their price objective for the stock from $6.00 to $18.00 in a research report on Tuesday, March 5th.

Get Our Latest Analysis on ARS Pharmaceuticals

ARS Pharmaceuticals Stock Performance

Shares of NASDAQ:SPRY opened at $9.13 on Monday. ARS Pharmaceuticals has a 52 week low of $2.55 and a 52 week high of $9.65. The company has a market capitalization of $881.05 million, a PE ratio of -16.02 and a beta of 0.78. The company has a 50 day moving average price of $7.60 and a two-hundred day moving average price of $5.75.

Insider Buying and Selling

In related news, CEO Richard E. Lowenthal sold 2,800 shares of the stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $9.00, for a total transaction of $25,200.00. Following the completion of the transaction, the chief executive officer now owns 1,744,994 shares in the company, valued at $15,704,946. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other ARS Pharmaceuticals news, CEO Richard E. Lowenthal sold 3,782 shares of the stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $9.02, for a total value of $34,113.64. Following the completion of the sale, the chief executive officer now owns 1,746,494 shares in the company, valued at $15,753,375.88. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Richard E. Lowenthal sold 2,800 shares of the stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $9.00, for a total transaction of $25,200.00. Following the completion of the sale, the chief executive officer now owns 1,744,994 shares of the company’s stock, valued at approximately $15,704,946. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 205,650 shares of company stock worth $1,866,512. 35.60% of the stock is owned by insiders.

Institutional Trading of ARS Pharmaceuticals

A number of hedge funds have recently modified their holdings of the stock. GSA Capital Partners LLP acquired a new stake in shares of ARS Pharmaceuticals during the 4th quarter worth about $632,000. Barclays PLC raised its stake in ARS Pharmaceuticals by 127.1% in the 4th quarter. Barclays PLC now owns 40,374 shares of the company’s stock worth $222,000 after purchasing an additional 22,597 shares in the last quarter. Nantahala Capital Management LLC raised its stake in ARS Pharmaceuticals by 45.3% in the 4th quarter. Nantahala Capital Management LLC now owns 1,596,504 shares of the company’s stock worth $8,749,000 after purchasing an additional 497,429 shares in the last quarter. Creative Planning raised its stake in ARS Pharmaceuticals by 11.7% in the 4th quarter. Creative Planning now owns 31,201 shares of the company’s stock worth $171,000 after purchasing an additional 3,270 shares in the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new stake in ARS Pharmaceuticals in the 4th quarter worth about $423,000. Institutional investors and hedge funds own 68.16% of the company’s stock.

ARS Pharmaceuticals Company Profile

(Get Free Report)

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.

Further Reading

Earnings History and Estimates for ARS Pharmaceuticals (NASDAQ:SPRY)

Receive News & Ratings for ARS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.